blocker

(redirected from sodium channel blocker)
Also found in: Dictionary, Thesaurus.

blocker

 [blok´er]
something that blocks or obstructs a passage or activity; see also antagonist and blocking agent.
α-blocker alpha-adrenergic blocking agent.
β-blocker (beta-blocker) beta-adrenergic blocking agent.
calcium channel blocker calcium channel blocking agent.
potassium channel blocker potassium channel blocking agent.
sodium channel blocker sodium channel blocking agent.

block·er

(blok'er),
An instrument used to obstruct a passage.

blocker

/block·er/ (blok´er) something that blocks or obstructs passage, activity, etc.
α-blocker  alpha-adrenergic blocking agent; see adrenergic blocking agent.
β-blocker  beta-adrenergic blocking agent; see adrenergic blocking agent.
calcium channel blocker  calcium channel blocking agent.
potassium channel blocker  potassium channel blocking agent.
sodium channel blocker  sodium channel blocking agent.

blocker

blocker

A popular term for anything which physically (e.g., a bed blocker, see there) or pharmacologically (e.g., a beta-blocker) impedes a process or activity.

block·er

(blok'ĕr)
1. An instrument used to obstruct a passage.
2. See: blocking agent

blocker

something that blocks or obstructs passage, activity, etc.
α-blocker, alpha-blocker
a drug that induces adrenergic blockade at α-adrenergic receptors.
β-blocker, beta-blocker
a drug that induces adrenergic blockade at either β1- or β2-adrenergic receptors, or both (see also beta-blocker).
calcium channel blocker
a drug that selectively inhibits the influx of calcium ions through a specific ion channel of cardiac muscle and smooth muscle cells (see also calcium channel blocker).
H2-receptor blocker
a drug, such as cimetidine that inhibits the secretion of gastric acid stimulated by histamine, pentagastrin, food and insulin, and also basal secretion; used in the treatment of peptic ulcer.
Mentioned in ?
References in periodicals archive ?
Spontaneous type 1 ECG, independently of history of syncope, predicted a higher risk in experiencing SCD than a non-diagnostic ECG which converted to coved-type ECG by exposure to sodium channel blockers during a mean follow-up of 24 [+ or -] 32 months.
The Brugada syndrome: can we predict the risk?
Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of [Beta]-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes.
Genotype and Severity of Long QT Syndrome
The use of sodium channel blockers to treat arrhythmias in cardiac patients demonstrates how marketing efforts can contradict sound medical practice.
The trial was halted because it clearly showed that the three sodium channel blockers being studied (encainide, flecainide, and morizicine) increased mortality--even though they had effectively corrected the arrhythmia.
A prescription for better prescriptions

Medical browser ?
Full browser ?